Acurx Pharma Launches Trial for Recurrent C. difficile Infection Treatment | NewsOut

Biotech and healthcare investors: Acurx Pharmaceuticals announced plans to launch a new clinical trial evaluating its antibiotic candidate IBZ in patients suffering from recurrent Clostridioides difficile (C. diff) infection.

Reporting from the New York Stock Exchange, Jane King explains the program will begin with an open-label pilot study targeting patients who have experienced at least three CDI episodes within the past 12 months. The company also stated its broader CDI treatment program is positioned to advance to Phase 3 international trials, pending funding.

#AcurxPharmaceuticals
#Cdiff
#Antibiotics
#ClinicalTrials
#DrugDevelopment
#InfectiousDisease
#BiotechNews
#HealthcareInnovation
#PharmaceuticalResearch
#MedicalResearch
#JaneKing
#NewsOut